Nephrocare Health Services IPO Allotment Status: Check GMP, Overall Subscription & Steps to Verify Status
The public subscription window for Nephrocare Health Services IPO closed last Friday on December 12, 2025. The allotment process for the Nephrocare Health Services IPO is expected to be finalised today on December 15, 2025, and the shares will be listed on both the NSE and the BSE. The tentative listing date is fixed as December 17, 2025.
NephroPlus is also known to deliver comprehensive dialysis care, including in-clinic haemodialysis and various advanced dialysis formats.
Know the procedure to check Nephrocare Health Services IPO allotment status online on the NSE, BSE and the registrar’s website.
Procedure to Check Nephrocare Health Services IPO Allotment Status Online On NSE
- Visit the NSE’s IPO allotment verification status page here.
- Select “Equity & SME IPO bid details”.
- In Select Symbol, select “Nephrocare Health Services”.
- Enter your PAN No. and application No.
- Click “Submit”.
Procedure to Check Nephrocare Health Services IPO Allotment Status Online On BSE
- Click here to visit the application status page.
- In Issue Type, “Equity”.
- In Issue Name, select “Nephrocare Health Services”.
- Enter your “Application No.” or “PAN No.”
- Click on “I am not a robot”.
- Click “Submit”.
Procedure to Check Nephrocare Health Services IPO Allotment Status on Kfin Technologies (Registrar to the issue)
- Visit the Kfin Technologies IPO allotment status page here.
- Click on any of the links.
- In Select IPO, select “Nephrocare Health Services”.
- Enter any of the following details.
- PAN
- App. No.
- Demat Account
- Enter the captcha and click “Submit”.
Nephrocare Health Services IPO Details
The NephroPlus (Nephrocare Health Services) IPO was a book-building issue of ₹871.05 crore and consisted of a fresh issue of ₹353.40 crore and an offer for sale of ₹517.64 crore. The price band was between ₹438 and ₹460 per share, with a lot size of 32 shares, requiring a minimum investment of ₹14,016 for retail investors.
Nephrocare Health Services IPO Overall Subscription Status
[December 12, 2025, end of the day]
On Day 3, Nephrocare Health Services' IPO was overall subscribed 14.08 times. The public issue was subscribed 2.36 times by the Retail Individual Investors (RIIs), 24.77 times by the Non Institutional Investors (NIIs), 26.82 times by the Qualified Institutional Buyers (QIBs) and 2.81 times by the Employees.
Explore other Upcoming IPOs on BSE and NSE.
Utilisation of Proceeds
The Company proposes to utilise the Net Proceeds towards funding the following objects:
- Capital expenditure by the Company for opening new dialysis clinics in India.
- Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed by the Company.
- General corporate purposes.
Nephrocare Health Services IPO GMP
As per media reports, the Grey Market Premium (GMP) of Nephrocare Health Services is reported at ₹34.5 over the IPO price.
Check out newly Listed IPOs on BSE and NSE.
NephroPlus (Nephrocare Health Services Ltd.) Business Overview
NephroPlus is the flagship brand of Nephrocare Health Services Ltd, a Hyderabad-based healthcare company founded in 2009 that operates a network of kidney care and dialysis clinics across India and select international markets. Under the NephroPlus brand, the company offers comprehensive renal care services, including in-centre haemodialysis, peritoneal dialysis, home dialysis, and related patient support programs.
The company is the only Indian dialysis services provider to have scaled internationally (Source: F&S Report), with a global network of 519 clinics, including 51 clinics in the Philippines, Uzbekistan, and Nepal (as of September 30, 2025).
Financially, Nephrocare Health Services reported operating revenue of approximately ₹755.8 crore in FY25, up from around ₹566.2 crore in FY24, reflecting strong growth as its clinic network expanded. Its profit after tax (PAT) for FY25 stood at about ₹67.1 crore.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.